Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01393_DB01432_nanopub.RAPXlur2QWITmferSABd2OngBpy68cLorF5DBhh3VjvXk#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01393_DB01432 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01393_DB01432 label "DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant. [drugbank_resource:DB01393_DB01432]" assertion.
- drugbank_resource:DB01393_DB01432 identifier "drugbank_resource:DB01393_DB01432" assertion.
- drugbank_resource:DB01393_DB01432 title "DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant." assertion.
- drugbank:DB01432 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01393_DB01432 assertion.
- drugbank:DB01393 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01393_DB01432 assertion.